Zevra Therapeutics 2024财年GAAP每股收益$(2.28)低于预期$(1.99),销售额$23.600M高于$20.514M估值

财报速递
12 Mar

Zevra Therapeutics(ZVRA)(纳斯达克代码:ZVRA)报告季度亏损$(2.28)每股,其低于分析师共识估计的$(1.99)14.57%。公司报告季度销售额$23.600百万,其高于分析师共识估计的$20.514百万15.04%。



以上内容来自Benzinga Earnings专栏,原文如下:

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(1.99) by 14.57 percent. The company reported quarterly sales of $23.600 million which beat the analyst consensus estimate of $20.514 million by 15.04 percent.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10